These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10075167)

  • 21. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
    Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
    Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine.
    Guy B; Chanthavanich P; Gimenez S; Sirivichayakul C; Sabchareon A; Begue S; Yoksan S; Luxemburger C; Lang J
    Vaccine; 2004 Sep; 22(27-28):3563-74. PubMed ID: 15315835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction.
    Johnson BW; Chambers TV; Crabtree MB; Guirakhoo F; Monath TP; Miller BR
    Am J Trop Med Hyg; 2004 Jan; 70(1):89-97. PubMed ID: 14971704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes.
    Etemad B; Batra G; Raut R; Dahiya S; Khanam S; Swaminathan S; Khanna N
    Am J Trop Med Hyg; 2008 Sep; 79(3):353-63. PubMed ID: 18784226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
    Sun W; Nisalak A; Gettayacamin M; Eckels KH; Putnak JR; Vaughn DW; Innis BL; Thomas SJ; Endy TP
    J Infect Dis; 2006 Jun; 193(12):1658-65. PubMed ID: 16703509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.
    Durbin AP; McArthur J; Marron JA; Blaney JE; Thumar B; Wanionek K; Murphy BR; Whitehead SS
    Hum Vaccin; 2006; 2(4):167-73. PubMed ID: 17012875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine.
    Rothman AL; Kanesa-thasan N; West K; Janus J; Saluzzo JF; Ennis FA
    Vaccine; 2001 Sep; 19(32):4694-9. PubMed ID: 11535318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys.
    Whitehead SS; Hanley KA; Blaney JE; Gilmore LE; Elkins WR; Murphy BR
    Vaccine; 2003 Oct; 21(27-30):4307-16. PubMed ID: 14505913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.
    Barban V; Mantel N; De Montfort A; Pagnon A; Pradezynski F; Lang J; Boudet F
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human CD4
    Angelo MA; Grifoni A; O'Rourke PH; Sidney J; Paul S; Peters B; de Silva AD; Phillips E; Mallal S; Diehl SA; Kirkpatrick BD; Whitehead SS; Durbin AP; Sette A; Weiskopf D
    J Virol; 2017 Mar; 91(5):. PubMed ID: 27974563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantity of dengue virus required to infect rhesus monkeys.
    Kraiselburd E; Gubler DJ; Kessler MJ
    Trans R Soc Trop Med Hyg; 1985; 79(2):248-51. PubMed ID: 2860743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes.
    Holman DH; Wang D; Raviprakash K; Raja NU; Luo M; Zhang J; Porter KR; Dong JY
    Clin Vaccine Immunol; 2007 Feb; 14(2):182-9. PubMed ID: 17192403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
    Blaney JE; Hanson CT; Firestone CY; Hanley KA; Murphy BR; Whitehead SS
    Am J Trop Med Hyg; 2004 Dec; 71(6):811-21. PubMed ID: 15642976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiplication and distribution of type 2 dengue and Japanese encephalitis viruses in Toxorhynchites splendens after intrathoracic inoculation.
    Yamamoto N; Kimura T; Ohyama A
    Arch Virol; 1987; 97(1-2):37-47. PubMed ID: 2891346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
    Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
    BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using recombinant DNA technology for the development of live-attenuated dengue vaccines.
    Lee HC; Butler M; Wu SC
    Enzyme Microb Technol; 2012 Jul; 51(2):67-72. PubMed ID: 22664189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
    Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines.
    Velzing J; Groen J; Drouet MT; van Amerongen G; Copra C; Osterhaus AD; Deubel V
    Vaccine; 1999 Mar; 17(11-12):1312-20. PubMed ID: 10195766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.